{"id":"cxa-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CXA-101 works by binding to the ferric uptake regulator (Fur) protein, thereby inhibiting the bacterial uptake of iron. This leads to a decrease in bacterial growth and proliferation. CXA-101 has shown efficacy against various Gram-negative bacteria.","oneSentence":"CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:11.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections"},{"name":"Complicated intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT04673175","phase":"PHASE4","title":"Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-01-10","conditions":"Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection","enrollment":17},{"nctId":"NCT04223752","phase":"PHASE1","title":"Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-04-17","conditions":"Nosocomial Pneumonia","enrollment":41},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06342115","phase":"PHASE4","title":"Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","status":"RECRUITING","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2025-03-26","conditions":"Febrile Neutropenia","enrollment":176},{"nctId":"NCT03581370","phase":"PHASE3","title":"Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2018-09-20","conditions":"Ventilator-associated Pneumonia","enrollment":80},{"nctId":"NCT05566665","phase":"","title":"Nosocomial Infections in ECMO Patients","status":"RECRUITING","sponsor":"Policlinico Hospital","startDate":"2023-01-01","conditions":"Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication","enrollment":200},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT04033029","phase":"","title":"Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2021-01-01","conditions":"Hemodiafiltration, Sepsis, Acute Kidney Injury","enrollment":20},{"nctId":"NCT06035055","phase":"PHASE4","title":"Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis","status":"UNKNOWN","sponsor":"Sunshine Coast Hospital and Health Service","startDate":"2023-10","conditions":"Bronchiectasis, Cystic Fibrosis, Pseudomonas Aeruginosa","enrollment":30},{"nctId":"NCT05061654","phase":"PHASE4","title":"CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients","status":"WITHDRAWN","sponsor":"Hamad Medical Corporation","startDate":"2022-08","conditions":"Neutropenia, Febrile, Hematologic Cancer","enrollment":""},{"nctId":"NCT03217136","phase":"PHASE2","title":"MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":94},{"nctId":"NCT03230838","phase":"PHASE2","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-26","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":134},{"nctId":"NCT03963297","phase":"","title":"Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination","status":"COMPLETED","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2019-03-01","conditions":"Antibiotic Resistant Strain","enrollment":747},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT04238390","phase":"PHASE3","title":"Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2022-01","conditions":"Bacteremia Caused by Gram-Negative Bacteria","enrollment":""},{"nctId":"NCT05267483","phase":"","title":"Evaluation of Usage Patterns and Outcomes in Patients Receiving Ceftolozane/Tazobactan (C/T) in Brazilian Hospitals","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-04-01","conditions":"Sepsis","enrollment":100},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT03002506","phase":"PHASE4","title":"Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns","status":"TERMINATED","sponsor":"Texas Tech University Health Sciences Center","startDate":"2017-08-21","conditions":"Burns, Pharmacokinetics","enrollment":6},{"nctId":"NCT04679610","phase":"","title":"In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram \"-\" Pathogens Isolated in Russia","status":"COMPLETED","sponsor":"The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)","startDate":"2017-02-01","conditions":"Nosocomial Infection","enrollment":700},{"nctId":"NCT03309657","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid","status":"COMPLETED","sponsor":"Royal Brisbane and Women's Hospital","startDate":"2018-02-01","conditions":"Pharmacokinetics","enrollment":10},{"nctId":"NCT02421120","phase":"PHASE4","title":"Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Joseph L. Kuti, PharmD","startDate":"2015-09","conditions":"Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection","enrollment":21},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":"Bacterial Infections, Fungal Infection","enrollment":900},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT04352855","phase":"","title":"Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.","status":"UNKNOWN","sponsor":"Semmelweis University","startDate":"2018-01-18","conditions":"Ventilator Associated Pneumonia, Antibiotic Resistant Infection","enrollment":55},{"nctId":"NCT04257812","phase":"","title":"Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-02-15","conditions":"Serious Infection","enrollment":20},{"nctId":"NCT04196608","phase":"","title":"In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients","status":"UNKNOWN","sponsor":"Emilio Bouza","startDate":"2019-11-01","conditions":"Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology","enrollment":1005},{"nctId":"NCT02962934","phase":"","title":"An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT","status":"COMPLETED","sponsor":"Royal Brisbane and Women's Hospital","startDate":"2016-11-30","conditions":"Gram-Negative Bacterial Infections","enrollment":18},{"nctId":"NCT02266706","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-17","conditions":"Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis","enrollment":43},{"nctId":"NCT02387372","phase":"PHASE1","title":"Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-02-05","conditions":"Critically Ill, Pneumonia","enrollment":37},{"nctId":"NCT02728089","phase":"PHASE3","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-14","conditions":"Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis","enrollment":115},{"nctId":"NCT02620774","phase":"PHASE1","title":"Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2016-02-19","conditions":"Diabetes, Wound Infection, Healthy Volunteers","enrollment":16},{"nctId":"NCT01853982","phase":"PHASE3","title":"Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-06-14","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":4},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122},{"nctId":"NCT00921024","phase":"PHASE2","title":"Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-06-30","conditions":"Complicated Urinary Tract Infection","enrollment":129},{"nctId":"NCT02739997","phase":"PHASE3","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-08","conditions":"Intra-abdominal Infection, Complicated Intra-abdominal Infection","enrollment":100},{"nctId":"NCT03510351","phase":"","title":"Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections","status":"UNKNOWN","sponsor":"Temple University","startDate":"2017-02-01","conditions":"Pseudomonas Infections, Pseudomonas Aeruginosa","enrollment":200},{"nctId":"NCT02508753","phase":"PHASE1","title":"Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06","conditions":"Healthy","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CXA-101","genericName":"CXA-101","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition. Used for Complicated urinary tract infections, Complicated intra-abdominal infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}